Photo of Howard L Kaufman,  MD

Howard L Kaufman, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4000


HLKaufman@mgh.harvard.edu

Howard L Kaufman, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Lecturer, Surgery, Harvard Medical School
  • Assistant in Surgery, Surgery, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Kaufman's research has focused on the development of oncolytic viruses and immunotherapy for the treatment of melanoma and other types of cutaneous malignancies. His lab has contributed to understanding how viruses induce immunogenic cell death and initiate host anti-tumor immunity. He led the first randomized phase III clinical trial of an oncolytic herpes simplex type 1 (HSV-1) virus encoding GM-CSF in patients with advanced melanoma, which resulted in FDA approval of the first oncolytic virus in cancer. He also helped establish the role of anti-PD-L1 treatment for patients with advanced Merkel cell carcinoma. He continues to focus on how to integrate oncolytic viruses into combination immunotherapy regimens to enhance systemic immunity and improve therapeutic responses in patients with cancer.

Publications

Powered by Harvard Catalyst
  • Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 2020. PubMed
  • Pai S, Blaisdell D, Brodie R, Carlson R, Finnes H, Galioto M, Jensen RE, Valuck T, Sepulveda AR, Kaufman HL. Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. J Immunother Cancer 2020. PubMed
  • Bommareddy PK, Peters C, Kaufman HL. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption. Methods Enzymol 2020; 635:167-184. PubMed
  • Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, Estupinian R, Aboelatta MM, Buddhadev S, Tarabichi S, Lee M, Li S, Medina DJ, Giurini EF, Gupta KH, Guevara-Aleman G, Rossi M, Nowicki C, Abed A, Goldufsky JW, Broucek JR, Redondo RE, Rotter D, Jhawar SR, Wang SJ, Kohlhapp FJ, Kaufman HL, Thomas PG, Gupta V, Kuzel TM, Reiser J, Paras J, Kane MP, Singer EA, Malhotra J, Denzin LK, Sant'Angelo DB, Rabson AB, Lee LY, Lasfar A, Langenfeld J, Schenkel JM, Fidler MJ, Ruiz ES, Marzo AL, Rudra JS, Silk AW, Zloza A. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci U S A 2019. PubMed
  • Hennessy ML, Bommareddy PK, Boland G, Kaufman HL. Oncolytic Immunotherapy. Surg Oncol Clin N Am 2019; 28:419-430. PubMed
  • Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 2019; 7:145. PubMed
  • Ugolini H, Bryan J, Hennessy M, Kaufman HL, D'Angelo S. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma. 2019; 23:E1-E9. PubMed
  • Kaufman HL, Bommareddy PK. Two roads for oncolytic immunotherapy development. J Immunother Cancer 2019; 7:26. PubMed
  • Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D. Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. J Biol Methods 2019. PubMed
  • Bommareddy PK, Rabkin SD, Kaufman HL. Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. Oncoimmunology 2019; 8:e1571390. PubMed
  • Bommareddy PK, Zloza A, Rabkin SD, Kaufman HL. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology 2019; 8:1591875. PubMed
  • Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. 2020; 9:1483. PubMed
  • Kaufman HL, Schwartz LH, William WN, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2018; 144:2245-2261. PubMed
  • Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 2018; 18:498-513. PubMed
  • Kaufman HL, Margolin K, Sullivan R. Management of Metastatic Melanoma in 2018. JAMA Oncol 2018; 4:857-858. PubMed
  • Bommareddy PK, Kaufman HL. Unleashing the therapeutic potential of oncolytic viruses. J Clin Invest 2019; 128:1258-1260. PubMed
  • Chan IS, Bhatia S, Kaufman HL, Lipson EJ. Immunotherapy for Merkel cell carcinoma: a turning point in patient care. J Immunother Cancer 2018; 6:23. PubMed
  • Kaufman HL, Hunger M, Hennessy M, Schlichting M, Bharmal M. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncol 2018; 14:255-266. PubMed
Hide
Member Summary Video